![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
NGM313, a Novel Once-Monthly Activator of bKlotho-FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Non-
Alcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin-Resistant Patients with NAFLD
|
|
|
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Sudha Shankar1, Mustafa R. Bashir2, Bryan A. Baxter1, Van Phung1, Andrew Z. Yan1, Stephen J. Rossi1, and Alex M. DePaoli1
1NGM Biopharmaceuticals, South San Francisco, CA 2Duke University, Durham, NC
![1212181](../images%20/121218/121218-1/1212181.gif)
![1212182](../images%20/121218/121218-1/1212182.gif)
![1212183](../images%20/121218/121218-1/1212183.gif)
![1212184](../images%20/121218/121218-1/1212184.gif)
![1212185](../images%20/121218/121218-1/1212185.gif)
![1212186](../images%20/121218/121218-1/1212186.gif)
![1212187](../images%20/121218/121218-1/1212187.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|